Navigation Links
GRANISOL™ (Granisetron) Oral Solution Eligible for Medicaid Reimbursement
Date:4/13/2011

CALIFON, N.J., April 13, 2011 /PRNewswire/ -- PediatRx, Inc. (OTCBB: PEDX) announced that the U.S. Centers for Medicare and Medicaid Services (CMS) recently notified state Medicaid agencies to include PediatRx's GRANISOL, NDC 52547-0801-30, in their list of reimbursed products. CMS funds the Medicaid and State Children Health Insurance Programs jointly with state governments.  These programs provide health insurance, including prescription drug coverage, to over 40 million low-income families,* and this number is expected to grow with the implementation of health care reform legislation.

Dr. Cameron Durrant, founder of PediatRx, said, "We are delighted to have reached an agreement with CMS to include PediatRx's GRANISOL on the list of reimbursed products for Medicaid. This means that individual state Medicaid programs can now add GRANISOL to their formularies, enabling patients enrolled in Medicaid access to the only once-daily oral solution of granisetron."

CMS provided in its notice to PediatRx two effective dates: an optional effective date of March 17, 2011, and a mandatory effective date of July 1, 2011. States can begin covering GRANISOL at their option any time between these two dates. Patients and health care providers can contact their state Medicaid program to find out if GRANISOL has been added at the current time. See http://www.cms.gov/MedicaidDrugRebateProgram/downloads/drugcon.pdf

Durrant continued, "We are acutely aware of the financial pressures on patients, including those who are not eligible for government-sponsored healthcare programs or are uninsured or underinsured. That is why we developed a co-pay assistance program, GRANI Cares, to support GRANISOL for eligible patients."

For patients who are not enrolled in Medicaid or Medicare, visit GRANI Cares:  http://www.121hm.com/offers/granisol

For disclaimer information, visit: http://www.121hm.com/offers/granisol/tandc.html

GRANISOL is indicated for the prevention of:

  • Nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin.
  • Nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation.

For full prescribing information, visit: http://www.pediatrx.com/products/pdf/granisol_pi.pdf

Selected Safety Information

  • GRANISOL is contraindicated in patients with known hypersensitivity to the drug or any of its components.
  • QT prolongation has been reported with granisetron. Therefore, GRANISOL Oral Solution should be used in caution with patients with pre-existing arrhythmias or cardiac conduction disorders, as this might lead to clinical consequences. Patients with cardiac disease, on cardio-toxic chemotherapy, with concomitant electrolyte abnormalities and/or on concomitant medications that prolong the QT interval are particularly at risk.
  • Safety and effectiveness in pediatric patients have not been established.
  • The most common side effects observed with administration of granisetron were headache, asthenia, constipation, diarrhea, dyspepsia, and abdominal pain.

*2009 U.S. Census Bureau.

For further information related to material contained in this release, please contact Holmes World Media Inc., +1 512 981 7369

About PediatRx, Inc.

PediatRx, Inc. (www.pediatrx.com) is a hospital specialty pharmaceutical company which focuses on treatments for patients suffering from serious conditions requiring hospitalization. PediatRx trades on the OTCBB under the ticker symbol PEDX.

Forward Looking Statements

This press release contains forward-looking statements.  Forward-looking statements are projections of events, revenues, income, future economics, research, development, reformulation, product performance or management's plans and objectives for future operations.  In some cases you can identify forward-looking statements by the use of terminology such as "may", "should", "anticipates", "believes", "expects", "intends", "forecasts", "plans", "future", "strategy", or words of similar meaning.  Forward-looking statements in this press release include those concerning expected growth in prescription drug coverage under Medicaid.  While these forward-looking statements and any assumptions upon which they are based are made in good faith and reflect current judgment regarding the direction of the business operations of PediatRx, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested in this press release.  These statements are predictions and involve known and unknown risks, uncertainties and other factors, including the risk that PediatRx cannot execute its business plan for lack of capital or other resources, distribution, partnering or licensing/acquisition opportunities, as well as the risks described in the periodic disclosure documents filed on EDGAR by PediatRx, copies of which are also available on the company's website.  Any of these risks could cause PediatRx or its industry's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by the forward-looking statements in this press release.  Except as required by applicable law, including the securities laws of the United States, PediatRx does not intend to update any of the forward-looking statements to conform these statements to actual results.

Further Information

PediatRx Inc.
Research & Business Development
Email: info@pediatrx.com

Shareholder Relations
+1 908 975 0753
Email: ir@pediatrx.com

Media Contact:
Bretton Holmes
bholmes@holmesworldmedia.com
512-981-7369

PD49 0411


'/>"/>
SOURCE PediatRx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ePharmaSolutions Launches New Application to Streamline Single Sign-On and User Account Provisioning for Sponsors Using Multiple Clinical Trial Technologies
2. UC San Diego chemists produce first high-resolution RNA nano square
3. delSECUR CORPORATION Announces Its Dissolution; and the Distribution of Its Asset to Its Lenders and Shareholders of the Corporation
4. Perceptive Informatics Introduces DataLabs® 5.0 EDC Solution, Unlocking New Clinical Trial Process Efficiencies
5. Announcing ValGenesis On-Demand SaaS Solution
6. Finesse Solutions Introduces New T700 cGMP Upstream Processing Platform Featuring G3 Hardware and Fully Integrated Single-Use Sensors
7. Finesse Solutions Showcases SmartBag with Fully Integrated Single-Use pH and pO2 Sensors for Rocker Bioreactors at Interphex 2011
8. M-3 Information, a Leader in Expert Behavioral Health Solutions, Launches M3Clinician.com
9. D3 Oncology Solutions Now Includes Via Oncology Pathways for Medical Oncology
10. 3-D nanoparticle in atomic resolution
11. A nano-solution to global water problem: Nanomembranes could filter bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... New York (PRWEB) , ... February 11, 2016 ... ... analytical instruments for more than 150 years, continues today to pursue the highest ... its line of analytical instruments: the AR9 Refractometer and the AR5 Refractometer. ...
(Date:2/10/2016)... , February 10, 2016 Early-career researchers ... Peru , Uganda and ... work in health and nutrition   Indonesia , ... Uganda and Yemen are being honored ... epidemiology. They are also celebrated for mentoring young women scientists who are ...
(Date:2/10/2016)... Tarrytown, New York, and New York, New York (PRWEB) , ... ... ... Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) today announced that ... discover and develop new vaccines and immunotherapies for infectious diseases and cancer. ...
(Date:2/10/2016)... ... 2016 , ... Benchmark Research, a fully-integrated network of ... principal investigators (PI) to the roles of Chief Medical Officer, Clinical Research and ... Chu, a Benchmark Research PI in the Austin office, will assume the role ...
Breaking Biology Technology:
(Date:2/9/2016)... Vigilant Solutions announces today that an agency used its Vigilant ... in a difficult homicide case. The agency then used Vigilant,s ... vehicle. Due to the ongoing investigation, the agency name and ... agency,s request. --> --> ... deceased at an intersection here in the City. He had ...
(Date:2/3/2016)... 2016 --> ... "Automated Fingerprint Identification System Market by Component (Hardware and ... & Finance, Government, Healthcare, and Transportation) and Geography - ... is expected to be worth USD 8.49 Billion by ... and 2020. The transformation and technology evolution from the ...
(Date:2/2/2016)... 2016 Checkpoint Inhibitors for Cancer – ... Are you interested in the future of cancer ... inhibitors. Visiongain,s report gives those predictions to 2026 ... level. Avoid falling behind in data or ... revenues those emerging cancer therapies can achieve. There ...
Breaking Biology News(10 mins):